Senti Bio to Participate in Upcoming Investor Conferences
Senti Biosciences (Nasdaq: SNTI), a biotechnology company specializing in next-generation cell and gene therapies, has announced its participation in two upcoming investor conferences. The company will be present at:
1. H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY, with a pre-recorded presentation available from September 9, 2024, at 7:00 a.m. ET.
2. Chardan's 8th Annual Genetic Medicines Conference in New York, NY, featuring a fireside chat on September 30, 2024, at 5:00 p.m. ET.
Senti Bio's flagship product, SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy, is currently in Phase 1 clinical trials. Investors can access webcasts and replays through the company's website for approximately 90 days following each event.
Senti Biosciences (Nasdaq: SNTI), un'azienda biotech specializzata in terapie cellulare e geniche di nuova generazione, ha annunciato la sua partecipazione a due conferenze per investitori in arrivo. L'azienda sarà presente a:
1. La 26a Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright a New York, NY, con una presentazione pre-registrata disponibile dal 9 settembre 2024, alle 7:00 a.m. ET.
2. La 8a Conferenza Annuale sui Medicinali Genetici di Chardan a New York, NY, con una conversazione informale il 30 settembre 2024, alle 5:00 p.m. ET.
Il prodotto di punta di Senti Bio, SENTI-202, una terapia cellulare investigativa CAR-NK a logica gated pronta all'uso, è attualmente in fase di sperimentazione clinica di Fase 1. Gli investitori possono accedere a webcast e registrazioni sul sito web dell'azienda per circa 90 giorni dopo ciascun evento.
Senti Biosciences (Nasdaq: SNTI), una empresa de biotecnología especializada en terapias celulares y genéticas de próxima generación, ha anunciado su participación en dos próximas conferencias para inversores. La empresa estará presente en:
1. La 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright en Nueva York, NY, con una presentación pregrabada disponible a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET.
2. La 8ª Conferencia Anual de Medicamentos Genéticos de Chardan en Nueva York, NY, que contará con un chat informal el 30 de septiembre de 2024, a las 5:00 p.m. ET.
El producto insignia de Senti Bio, SENTI-202, una terapia celular investigativa CAR-NK de acceso inmediato, se encuentra actualmente en ensayos clínicos de Fase 1. Los inversores pueden acceder a las transmisiones web y las repeticiones a través del sitio web de la empresa durante aproximadamente 90 días después de cada evento.
센티 바이오사이언스(Senti Biosciences)(Nasdaq: SNTI)는 차세대 세포 및 유전자 치료에 특화된 생명공학 회사로, 다가오는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 다음과 같이 참석할 예정입니다:
1. H.C. 웨인라이트 26회 글로벌 투자 회의가 뉴욕, NY에서 열리며, 2024년 9월 9일 오전 7시(동부 표준시)부터 시청 가능한 사전 녹화 발표가 제공됩니다.
2. 차르단 8회 유전자 의약품 회의가 뉴욕, NY에서 열리며, 2024년 9월 30일 오후 5시(동부 표준시)에 진행되는 대화도 포함되어 있습니다.
센티 바이오의 주력 제품인 SENTI-202는 즉시 사용 가능한 CAR-NK 연구 세포 치료제로 현재 1상 임상 시험 중입니다. 투자자들은 각 이벤트 후 약 90일 동안 회사 웹사이트를 통해 웹캐스트와 재방송에 액세스할 수 있습니다.
Senti Biosciences (Nasdaq: SNTI), une société de biotechnologie spécialisée dans les thérapies cellulaires et géniques de nouvelle génération, a annoncé sa participation à deux conférences pour investisseurs à venir. L'entreprise sera présente à :
1. La 26ème Conférence Annuelle Mondiale sur l'Investissement de H.C. Wainwright à New York, NY, avec une présentation préenregistrée disponible à partir du 9 septembre 2024, à 7h00 ET.
2. La 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan à New York, NY, comprenant une discussion informelle le 30 septembre 2024, à 17h00 ET.
Le produit phare de Senti Bio, SENTI-202, une thérapie cellulaire expérimentale CAR-NK prête à l'emploi, est actuellement en essais cliniques de Phase 1. Les investisseurs peuvent accéder aux webinaires et aux rediffusions via le site web de l'entreprise pendant environ 90 jours suivant chaque événement.
Senti Biosciences (Nasdaq: SNTI), ein Biotechnologieunternehmen, das sich auf nächste Generation der Zell- und Gentherapien spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird an folgenden Veranstaltungen teilnehmen:
1. Der 26. jährliche globale Investorenkonferenz von H.C. Wainwright in New York, NY, mit einer vorab aufgenommenen Präsentation, die ab dem 9. September 2024, um 7:00 Uhr ET, verfügbar sein wird.
2. Die 8. jährliche Konferenz für genetische Medikamente von Chardan in New York, NY, die ein informelles Gespräch am 30. September 2024, um 17:00 Uhr ET, bietet.
Das Hauptprodukt von Senti Biosciences, SENTI-202, eine sofort verfügbare CAR-NK-Experimentelle Zelltherapie, befindet sich derzeit in klinischen Studien der Phase 1. Investoren können über die Website des Unternehmens für etwa 90 Tage nach jeder Veranstaltung auf Webcasts und Aufzeichnungen zugreifen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences:
- H.C. Wainwright’s 26th Annual Global Investment Conference
Format: Presentation and 1x1 Meetings
Location: New York, NY
Please click here to access the pre-recorded presentation (available September 9, 2024, at 7:00 a.m. ET) - Chardan's 8th Annual Genetic Medicines Conference
Format: Fireside Chat and 1x1 Meetings
Date: September 30, 2024, at 5:00 p.m. ET
Location: New York, NY
Please click here to access the live webcast
Archived replays can be accessed through the Events & Presentations section of the Senti Bio website and will be available for approximately 90 days following each event. For additional information or to schedule a one-on-one meeting, please email investors@sentbio.com.
About SENTI-202
SENTI-202 is a Logic Gated off-the-shelf chimeric antigen receptor natural killer (“CAR-NK”) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (“MDS”), while sparing healthy bone marrow cells. SENTI-202 has three main components. First, the OR GATE, which is an activating CAR that targets CD33 and FLT3. By targeting either or both of these antigens, SENTI-202 could effectively kill both the leukemic blasts and leukemic stem cells that form an important basis for AML disease. Second, the NOT GATE, which is designed to recognize the healthy cells and protect those healthy cells from being killed. Third, the calibrated-release IL-15 technology, which is designed to significantly increase cell persistence, expansion and activity of both the CAR- NK cells and the host immune cells. The NK cells used to construct SENTI-202 are sourced from healthy adult donors, which have been screened based on a set of criteria that reflect manufacturability and product quality, and are then cryopreserved prior to use in manufacturing to minimize variability. Senti Bio is currently enrolling adult patients with r/r CD33 and/or FLT3 expressing hematologic malignancies in a Phase 1 clinical trial for SENTI-202, which can be a potential first-in-class allogeneic treatment for AML/MDS patients. Senti Bio anticipates releasing initial clinical trial results for SENTI-202 by year-end 2024.
Senti Bio has published SENTI-202 preclinical data demonstrating the potential of Logic Gated CAR-NK cell therapy for the treatment of AML.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. The Company’s wholly-owned pipeline utilizes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships with Spark Therapeutics and BlueRock Therapeutics.
Forward-Looking Statements
This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Senti Bio’s participation in upcoming conferences, expectations regarding Senti Bio’s growth, strategy, progress and timing of its clinical trials for SENTI-202; the timing of availability of data from the ongoing Phase 1 clinical trial of SENTI-202; expectations regarding the anticipated dosing of patients and availability of data from clinical trials, and the timing thereof; the ability to initiate new clinical programs as well as statements about the potential attributes and benefits of Senti Bio’s platform technology. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial start up, clinical studies, patient enrollment, and GMP manufacturing startup activities, (vii) Senti Bio’s dependence on third parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of the grant from CIRM, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (“SEC”) on August 13, 2024, and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Senti Bio Contacts
Investors: investors@sentibio.com
Media: media@sentibio.com
FAQ
What investor conferences will Senti Biosciences (SNTI) attend in September 2024?
When is Senti Biosciences' (SNTI) presentation at the H.C. Wainwright conference?
What is the date and time of Senti Biosciences' (SNTI) fireside chat at the Chardan conference?
What is SENTI-202 and what stage of development is it in?
How long will the webcasts of Senti Biosciences' (SNTI) conference presentations be available?
